Genomic Vision signs a distribution agreement with CliniSciences
Saturday, June 24, 2023
Genomic Vision (FR0011799907 - GV, - the "Company"), a biotechnology company listed on Euronext developing products and services for the precise characterization of DNA sequences, is pleased to announce an agreement exclusive European distribution with CliniSciences.
CliniSciences is one of the main European distributors of innovative products and services in the field of research in life sciences, and more particularly in oncology. CliniSciences and Genomic Vision will work closely together to leverage their respective resources, industry knowledge and client relationships. The agreement allows Genomic Vision to offer its innovative technology, products and services in 15 European countries, extending the reach of its cutting-edge genomics solutions in these key markets.
The collaboration with CliniSciences fits directly into the refocused strategy of Genomic Vision. Using CliniSciences' extensive distribution networks, Genomic Vision is poised to expand the reach of its genomics solutions. This strategic move will not only strengthen Genomic Vision's ability to improve bioproduction standards, but also support the advancement of advanced cell and gene therapies. It underscores Genomic Vision's commitment to providing accurate genomic characterization at scale, encouraging innovation and excellence in this field.
Outside of Europe, Genomic Vision will continue to market its products and services independently. This will allow the company to maintain its existing distribution channels and established relationships with customers around the world. By ensuring a seamless experience for its global customer base, the company can continue to serve researchers, clinicians and other stakeholders with the same level of quality and reliability that they have come to expect from Genomic Vision.
Aaron Bensimon, CEO of Genomic Vision, said , “This partnership with CliniSciences is a major step forward in advancing Genomic Vision's strategic pivot to biomanufacturing and drug discovery. Our collaboration brings together shared resources, deep industry knowledge and strong customer relationships to improve adoption of Genomic Vision's products across Europe. By leveraging CliniSciences' well-established distribution channels, we are able to extend the reach of our innovative technologies more effectively. We are optimistic about the potential of this partnership and look forward to reporting on our progress in the future.
Tushendan Rasiah, Managing Director of CliniSciences, commented: “ Through this distribution agreement with Genomic Vision, CliniSciences strengthens its position as a commercial leader in the field of cutting-edge products and services for life science research. We are excited to expand our product offering in two main areas . We emphasize the quality control of genetically modified cells used in the production of recombinant proteins, as well as in the field of gene and cell therapy. Finally, new screening tests for oncology drugs, including DDR drugs, are paving the way for a personalized medicine approach.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products and services for the precise characterization of genome modifications. We provide integrated, high-precision genomic analysis solutions to improve quality control and standards in biomanufacturing and gene therapies. Using molecular combing technology and artificial intelligence, the company provides quantitative and robust measurements needed to reliably characterize transformed cell lines and predict their performance, especially in the context of bio-manufacturing processes. and gene therapies. Genomic Vision's molecular combing technology has further applications in drug development targeting DNA replication and DNA damage response mechanisms, visualizing replication kinetics as well as length maintenance telomeres. Genomic Vision, whose head office is located in Bagneux, near Paris, is a public company listed in compartment C of the regulated market of Euronext in Paris (Euronext: GV - ISIN: FR0011799907).
For more information, visit www.genomicvision.com
ABOUT CLINISCIENCES
The CliniSciences group is a European distributor of reagents and equipment for scientific research and medical diagnosis. It assists more than 350,000 customers daily through its 130 employees in 15 countries, the majority of whom are scientists, most of them with doctorates in science. CliniSciences has more than 40 years of experience in the field of oncology diagnostics with a wide range of in vitro diagnostic products manufactured by partners recognized for the quality of their products. The objective of CliniSciences is to contribute to the development of scientific innovation in the world by participating in the promotion of inventions resulting from laboratories, particularly in the field of oncology.
For more information, please visit www.clinisciences.com
